vadimezan has been researched along with verubulin in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (verubulin) | Trials (verubulin) | Recent Studies (post-2010) (verubulin) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 23 | 3 | 17 |
| Protein | Taxonomy | vadimezan (IC50) | verubulin (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0028 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.0056 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0084 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 1 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
1 other study(ies) available for vadimezan and verubulin
| Article | Year |
|---|---|
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |